Japanese study looks for EGFR mut’ns throughout tumor: longer surv w/EGFR inhib if all samples show mut’n vs some areas do, others don’t.

Related posts:

Not surprisingly, having EGFR … Not surprisingly, having EGFR mut’n gives same good surv w/adv NSCLC regardles...

Asian study comparing 1st line… Asian study comparing 1st line Iressa vs. chemo in pts w/EGFR mut’n confirm...

Study of contribution of EUS/E… Study of contribution of EUS/EBUS added to surgical staging: sensitivity of detectin...

A study shows that 78% of earl… A study shows that 78% of early NSCLC pts in US had suboptimal resection as define...

UK study of Tarceva vs. placeb… UK study of Tarceva vs. placebo in non-chemo candidates actually shows improvemen...